TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum" or the "Company"), has reported its audited financial and operational results for the fourth quarter and year ended December 31, 2025.
Fourth Quarter and Full Year 2025 Financial Results
Quantum's strong balance sheet and overall progress continue, and management is confident that there is sufficient working capital, as of the date of filing these Financial Statements, to carry out its operations over the next 24 months. Cash on hand and fair market value of digital assets as of the date of filing these Financial Statements is $11.3 million USD. Management believes there is sufficient cash to sustain basic operations beyond January 2028. Digital assets continue to be used as a treasury function of the Company to allow diversification with high liquidity. The Company's ability to secure financing from multiple distinct sources in 2025, ranging from convertible debt, institutional loans, and the monetization of its loan portfolio, reflects a material improvement in capital market access and funding flexibility compared to the prior year.
For the year ended December 31, 2025, Operating Expenses were reduced to $15.3 million USD compared to $16.1 million USD in the same period of 2024, an improvement of approximately 5%.
As of the date of filing, the Company had reduced trade and other payables by approximately 50%, from $4.1 million on December 31, 2025, to $2.0 million, reflecting improved working capital management.
For the year ended December 31, 2025, external research and development fees decreased to $2.8 million USD compared to $6.1 million USD in the same period of 2024 as a result of phase 1 clinical trials ending, as well as R&D tax credit initiatives provided by the Australian government during FY2025.
For the year ended December 31, 2025, General and Administrative expenses decreased to $9.0 million USD compared to $9.4 million USD in the same period of 2024 as a result of operational efficiencies.
Fourth Quarter & Subsequent 2025 Corporate Highlights
unbuzzd Peer Review Journal Publication of Positive Game Changing Results
An international peer-reviewed journal published the results of the double-blind, randomized, placebo-controlled crossover design clinical trial (NCT06505239) of dietary supplement product unbuzzd, investigating its effects on alcohol intoxication and alcohol metabolism. The publication, Effect of a Novel Dietary Supplement, FSD-F2R6, on Alcohol Metabolism, Mental Clarity, and Hangover Symptoms after Alcohol Consumption: A Randomized, Double-Blind, Placebo-Controlled Crossover Study, can be found at: https://zenodo.org/records/18873638
Results of data analysis show definitively that unbuzzd accelerated the rate at which Blood Alcohol Concentration ("BAC") was reduced in study subjects, while simultaneously reducing the symptoms of intoxication and hangover;
Health Canada has granted a Product License (PN 80144141) for Quantum's natural health product, Qlarity, that Enhances Energy and Promotes Metabolism, Mental Alertness and Cognitive Performance;
Quantum licensed a similar product, as a dietary supplement, for sale in the United States under the brand name unbuzzd™ (unbuzzd.com). This Product License from Health Canada permits Quantum to sell Qlarity in Canada;
Unbuzzd has hired MNP as auditors to prepare for a possible Initial Public Offering (IPO);
Unbuzzd has launched a Regulation D 506(c) offering to raise up to $5.0 million USD to support growth and distribution of unbuzzd, as well as fund a go-public event;
Multiple Sclerosis Drug Candidate Lucid-21-302 ("Lucid-MS") Advances:
Phase 1 oral toxicity studies of 3 and 6 months of Lucid-MS are complete and ...
